Ardelyx (ARDX) reported $74.11 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 61.1%. EPS of -$0.17 for the same period compares to -$0.11 a year ago.The reported revenue represents a surprise of -8.14% over the Zacks Consensus Estimate of $80.68 million. With the consensus EPS estimate being -$0.10, the EPS surprise was -70.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Ardelyx (ARDX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -70%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.02 per share when it actually produced earnings of $0.02, delivering no surprise.Over the last four quarters, the company has surpassed ...

Financial Data and Key Metrics Changes - The company reported total revenues of $74.1 million for Q1 2025, a 61% increase compared to $46 million in Q1 2024 [19] - Net sales revenue for IBSRELA was $44.4 million, reflecting a 57% increase year-over-year [19] - Exposa generated net sales revenue of $23.4 million, up approximately 55% from $15.2 million in the same quarter last year [19][21] - The company recorded a net loss of approximately $41.1 million or $0.17 per share, compared to a net loss of $26.5 million or $0.11 per share in the prior year [23] Business Line Data and Key Metrics Changes - IBSRELA experienced strong prescription demand, with one of the highest prescription demand quarters to date [6] - Exposa grew by 30% year-over-year when excluding a one-time gross to net adjustment for return reserve release [7][21] - The gross to net deduction for IBSRELA was 34.8%, expected to improve throughout the year [20] Market Data and Key Metrics Changes - The IBS C market traditionally contracts in Q1, which was observed this year, but the company remains optimistic about recovery in subsequent quarters [31] - The dialysis market is undergoing significant disruption due to the loss of Medicare Part D coverage for phosphate-lowering therapies, impacting Exposa's market dynamics [8] Company Strategy and Development Direction - The company is focused on driving strong commercial execution for IBSRELA and navigating access complexities for Exposa [10] - The strategic imperatives include raising awareness of IBSRELA and positioning it as a first-line treatment for appropriate patients [13] - The company aims to achieve peak annual net sales revenue of over $1 billion for IBSRELA and $750 million for Exposa [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IBSRELA and Exposa, citing strong patient demand and effective commercial strategies [5][10] - The company is closely monitoring market dynamics and will provide further updates as the landscape evolves [9] - Management remains committed to building long-term value for shareholders despite current market challenges [10] Other Important Information - The company received a $5 million milestone payment from a partner in China following the approval of a cannabinoid for hyperphosphatemia [22] - Research and development expenses increased to $14.9 million, reflecting greater engagement with scientific and medical communities [22] Q&A Session Summary Question: Expectations for the IBS C market improvement in Q2 - Management expects the IBS C market to improve as the year progresses, based on strong prescription demand observed in Q1 [31][32] Question: Details on the return reserve and its impact - The return reserve was deemed unnecessary due to zero returns and limited bottles in distribution, leading to modest improvements in gross to net going forward [29][30] Question: Insights on the Q1 contraction and its differences from previous years - The contraction is consistent with historical trends, but the company remains optimistic about future growth [35][37] Question: Long-term gross to net targets and updates on the China launch - Long-term guidance for gross to net is expected to be around 30% plus or minus 5% [40] Question: Discrepancies between reported revenue and script data for IBSRELA - Management acknowledged fluctuations in scripts and emphasized the importance of focusing on guidance rather than individual quarter performance [48][50] Question: Metrics for assessing the expanded field force's impact - Key metrics include increases in activity, new riders, and new/refill prescriptions, all of which showed positive trends in Q1 [56][57] Question: Updates on the Kidney Patient Act and potential external asset acquisitions - The Kidney Patient Act is viewed as a call option, and the company is actively pursuing external assets in renal and GI spaces [102][104]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-Q ____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ARDELYX, INC. (Exact Name of Registrant as Specified in Its Charter) ____________________________________________________ Delaware 26-1303944 (State or Other J ...

Revenue Performance - Ardelyx reported total revenue of $74.1 million for Q1 2025, reflecting a 61% year-over-year growth[2] - IBSRELA net product sales revenue reached $44.4 million in Q1 2025, showing a significant year-over-year growth of approximately 57%[5] - XPHOZAH net product sales revenue was $23.4 million in Q1 2025, with a 30% growth compared to the same period in 2024, excluding a $3.8 million release of prior periods' estimated product returns[6] - Total revenues for the three months ended March 31, 2025, were $74,114 million, a 61.1% increase from $46,023 million in the same period of 2024[27] - Total product sales, net, reached $67,814 million, up 55.8% from $43,512 million year-over-year[27] - Licensing revenue surged to $5,020 million, compared to just $17 million in the same quarter of 2024[27] Financial Position - The company ended Q1 2025 with $214.0 million in cash, cash equivalents, and investments, down from $250.1 million at the end of 2024[8] Sales Forecast - Ardelyx expects full-year 2025 U.S. net product sales revenue for IBSRELA to be between $240.0 million and $250.0 million[5] Expenses - Research and development expenses for Q1 2025 were $14.9 million, up from $10.6 million in Q1 2024, reflecting increased engagement with the scientific community[12] - Selling, general and administrative expenses rose to $83.2 million in Q1 2025, compared to $53.0 million in Q1 2024, primarily due to commercialization costs[12] - Research and development expenses increased to $14,938 million, a 41.1% rise compared to $10,579 million in the prior year[27] - Selling, general and administrative expenses rose significantly to $83,222 million, up 57.5% from $52,994 million in the previous year[27] - Total cost of goods sold was $12,303 million, up from $7,128 million, reflecting a 72.5% increase year-over-year[27] Net Loss - The net loss for Q1 2025 was $41.1 million, or $(0.17) per share, compared to a net loss of $26.5 million, or $(0.11) per share, in Q1 2024[12] - The net loss for the quarter was $41,144 million, compared to a net loss of $26,518 million in the same quarter of 2024[27] - Net loss per share of common stock was $0.17, compared to $0.11 in the prior year[27] - The company reported a loss from operations of $36,349 million, an increase from a loss of $24,678 million in the same period last year[27] Leadership Changes - Ardelyx appointed Merdad Parsey, M.D. Ph.D., to its Board of Directors and Laura A. Williams, M.D., M.P.H., as the first Chief Patient Officer in April 2025[8] Milestone Payment - The company received a $5.0 million milestone payment from Fosun Pharma following the approval of tenapanor in China for hyperphosphatemia[8]

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-c ...

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Ardelyx will hold a conference call on May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update for the first quarter of 2025 [1] - Participants can join the call by dialing (877) 346-6112 for domestic calls or (848) 280-6350 for international calls [2] - The conference call will be available via live audio webcast on the company's website and will be archived for 30 days [2]

WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also ...

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first- in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post- hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to be held Apr ...

Award established to recognize leaders in the field of chronic kidney disease advocacyWALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is proud to announce on World Kidney Day that Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield and David M. White are the first recipients of the Derek Forfan ...